rewirebio.iobenchmarks
Evidence and investigation

Contested results

Where one study disagrees with what other studies report for the same models, and what we are doing to resolve each case.

These are automatic leads, not findings of error. Each release, a check compares how every study ranks the models it shares with other studies. It flags a study that reverses the order the others agree on, or whose gap to a shared reference model lies well outside theirs. Different tasks, populations or metrics often explain a flag.

A flag never hides a result. Flagged results stay in every table, page and download, marked Contested. A result is withheld only when a reviewer marks it disputed.

How the check works, and how each follow-up is recorded: discrepancies between studies.

In this release

  • 121open
  • 5settled
  • 7resolved
  • 1medium severity
  • 132low severity

Release 2026-11-02-a7f03c9e55a5 · 133 findings in all · rules version 4

Findings

Status: All · Open · Settled · Resolved

Severity: All · Medium · Low

State: All · Not yet reviewed · Under investigation · Explained · Confirmed error · Not a real disagreement

Showing findings that compare ESM-1b. All models

12 findings match, most severe first.

MVP and ESM-1b: Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods reverses the order

  • Low severity
  • Not yet reviewed
  • Ordering reversal
  • Same task, different protocols

Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods ranks MVP above ESM-1b in 2 of 2 comparisons; 2 of 2 other studies rank ESM-1b above MVP.

2 papers rank ESM-1b above MVP in all 13 of their comparisons. Brandes et al. 2023 ranks MVP above ESM-1b in all 2 comparisons that are not ties (2 are ties).

Comparisons in which each paper scores ESM-1b or MVP higher2 other papers: ESM-1b higher in 13, MVP higher in 0, 0 ties. Brandes et al. 2023 (disagrees): ESM-1b higher in 0, MVP higher in 2, 2 ties.2 other papers13 ESM-1b higher13Disagrees: Brandes et al. 2023Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods2 tie22 MVP higher2
ESM-1b higherTieMVP higher
Compared
MVP, ESM-1b

Not reviewed yet.

BayesDel and ESM-1b: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) reverses the order

  • Low severity
  • Not yet reviewed
  • Ordering reversal
  • Same task, different protocols

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks ESM-1b above BayesDel in 6 of 7 comparisons; 2 of 2 other studies rank BayesDel above ESM-1b.

2 papers rank BayesDel above ESM-1b in all 10 of their comparisons. Livesey and Marsh 2025 ranks ESM-1b above BayesDel in 6 of its 7 comparisons and BayesDel higher in 1.

Comparisons in which each paper scores BayesDel or ESM-1b higher2 other papers: BayesDel higher in 10, ESM-1b higher in 0, 0 ties. Livesey and Marsh 2025 (disagrees): BayesDel higher in 1, ESM-1b higher in 6, 0 ties.2 other papers10 BayesDel higher10Disagrees: Livesey and Marsh 2025Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)1 BayesDel higher16 ESM-1b higher6
BayesDel higherTieESM-1b higher
Compared
BayesDel, ESM-1b

Not reviewed yet.

ESM-1b and EVE: Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods reverses the order

  • Low severity
  • Under investigation
  • Ordering reversal
  • Same task, different protocols

Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods ranks ESM-1b above EVE in 6 of 6 comparisons; 2 of 2 other studies rank EVE above ESM-1b.

2 papers rank EVE above ESM-1b in 22 of their 26 comparisons and ESM-1b higher in 1; 3 are ties. Brandes et al. 2023 ranks ESM-1b above EVE in all 6 comparisons that are not ties (2 are ties).

Comparisons in which each paper scores EVE or ESM-1b higher2 other papers: EVE higher in 22, ESM-1b higher in 1, 3 ties. Brandes et al. 2023 (disagrees): EVE higher in 0, ESM-1b higher in 6, 2 ties.2 other papers22 EVE higher223 tie31 ESM-1b higherDisagrees: Brandes et al. 2023Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods2 tie26 ESM-1b higher6
EVE higherTieESM-1b higher
Compared
ESM-1b, EVE

1 follow-up action, latest 23 October 2026. Next check 6 November 2026

MetaLR and ESM-1b: Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods reverses the order

  • Low severity
  • Not yet reviewed
  • Ordering reversal
  • Same task, different protocols

Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods ranks MetaLR above ESM-1b in 2 of 2 comparisons; 2 of 2 other studies rank ESM-1b above MetaLR.

2 papers rank ESM-1b above MetaLR in all 13 of their comparisons. Brandes et al. 2023 ranks MetaLR above ESM-1b in all 2 comparisons that are not ties (2 are ties).

Comparisons in which each paper scores ESM-1b or MetaLR higher2 other papers: ESM-1b higher in 13, MetaLR higher in 0, 0 ties. Brandes et al. 2023 (disagrees): ESM-1b higher in 0, MetaLR higher in 2, 2 ties.2 other papers13 ESM-1b higher13Disagrees: Brandes et al. 2023Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods2 tie22 MetaLR higher2
ESM-1b higherTieMetaLR higher
Compared
MetaLR, ESM-1b

Not reviewed yet.

MetaSVM and ESM-1b: Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods reverses the order

  • Low severity
  • Not yet reviewed
  • Ordering reversal
  • Same task, different protocols

Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods ranks MetaSVM above ESM-1b in 2 of 2 comparisons; 2 of 2 other studies rank ESM-1b above MetaSVM.

2 papers rank ESM-1b above MetaSVM in all 13 of their comparisons. Brandes et al. 2023 ranks MetaSVM above ESM-1b in all 2 comparisons that are not ties (2 are ties).

Comparisons in which each paper scores ESM-1b or MetaSVM higher2 other papers: ESM-1b higher in 13, MetaSVM higher in 0, 0 ties. Brandes et al. 2023 (disagrees): ESM-1b higher in 0, MetaSVM higher in 2, 2 ties.2 other papers13 ESM-1b higher13Disagrees: Brandes et al. 2023Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods2 tie22 MetaSVM higher2
ESM-1b higherTieMetaSVM higher
Compared
MetaSVM, ESM-1b

Not reviewed yet.

MutPred and ESM-1b: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) reverses the order

  • Low severity
  • Not yet reviewed
  • Ordering reversal
  • Same task, different protocols

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks ESM-1b above MutPred in 6 of 7 comparisons; 2 of 2 other studies rank MutPred above ESM-1b.

3 papers rank MutPred above ESM-1b in 8 of their 11 comparisons and ESM-1b higher in 1; 2 are ties. Of those papers, ProteinGym ranks ESM-1b higher on its own (1 of 1). Livesey and Marsh 2025 ranks ESM-1b above MutPred in 6 of its 7 comparisons and MutPred higher in 1.

Comparisons in which each paper scores MutPred or ESM-1b higher3 other papers: MutPred higher in 8, ESM-1b higher in 1, 2 ties. Livesey and Marsh 2025 (disagrees): MutPred higher in 1, ESM-1b higher in 6, 0 ties.3 other papers8 MutPred higher82 tie21 ESM-1b higher1Disagrees: Livesey and Marsh 2025Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)1 MutPred higher16 ESM-1b higher6
MutPred higherTieESM-1b higher
Compared
MutPred, ESM-1b

Not reviewed yet.

VEST4 and ESM-1b: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) reverses the order

  • Low severity
  • Not yet reviewed
  • Ordering reversal
  • Same task, different protocols

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks ESM-1b above VEST4 in 6 of 7 comparisons; 2 of 2 other studies rank VEST4 above ESM-1b.

2 papers rank VEST4 above ESM-1b in 7 of their 10 comparisons and ESM-1b higher in 1; 2 are ties. Livesey and Marsh 2025 ranks ESM-1b above VEST4 in 6 of its 7 comparisons and VEST4 higher in 1.

Comparisons in which each paper scores VEST4 or ESM-1b higher2 other papers: VEST4 higher in 7, ESM-1b higher in 1, 2 ties. Livesey and Marsh 2025 (disagrees): VEST4 higher in 1, ESM-1b higher in 6, 0 ties.2 other papers7 VEST4 higher72 tie21 ESM-1b higher1Disagrees: Livesey and Marsh 2025Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)1 VEST4 higher16 ESM-1b higher6
VEST4 higherTieESM-1b higher
Compared
VEST4, ESM-1b

Not reviewed yet.

ESM-1b and Tranception: ProteinGym: Large-Scale Benchmarks for Protein Fitness Prediction and Design and Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) disagree

  • Low severity
  • Not yet reviewed
  • two-study-conflict
  • different-task

ProteinGym: Large-Scale Benchmarks for Protein Fitness Prediction and Design ranks Tranception above ESM-1b in 15 of 19 comparisons; Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks ESM-1b above Tranception in 7 of 7 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank ESM-1b above Tranception in 11 of their 26 comparisons and Tranception higher in 15. Of those papers, ProteinGym ranks Tranception higher on its own (15 of 19).

Comparisons in which each paper scores ESM-1b or Tranception higher2 other papers: ESM-1b higher in 11, Tranception higher in 15, 0 ties.2 other papers11 ESM-1b higher1115 Tranception higher15
ESM-1b higherTieTranception higher
Compared
ESM-1b, Tranception

Not reviewed yet.

CARP and ESM-1b: ProteinGym: Large-Scale Benchmarks for Protein Fitness Prediction and Design and Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) disagree

  • Low severity
  • Not yet reviewed
  • two-study-conflict
  • different-task

ProteinGym: Large-Scale Benchmarks for Protein Fitness Prediction and Design ranks ESM-1b above CARP in 14 of 18 comparisons; Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks CARP above ESM-1b in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank CARP above ESM-1b in 10 of their 25 comparisons and ESM-1b higher in 14; 1 is a tie. Of those papers, ProteinGym ranks ESM-1b higher on its own (14 of 19).

Comparisons in which each paper scores CARP or ESM-1b higher2 other papers: CARP higher in 10, ESM-1b higher in 14, 1 tie.2 other papers10 CARP higher101 tie14 ESM-1b higher14
CARP higherTieESM-1b higher
Compared
CARP, ESM-1b

Not reviewed yet.

MutFormer and ESM-1b: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • two-study-conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutFormer above ESM-1b in 7 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks ESM-1b above MutFormer in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank MutFormer above ESM-1b in 7 of their 13 comparisons and ESM-1b higher in 6. Of those papers, An openly licensed benchmark… ranks ESM-1b higher on its own (6 of 6).

Comparisons in which each paper scores MutFormer or ESM-1b higher2 other papers: MutFormer higher in 7, ESM-1b higher in 6, 0 ties.2 other papers7 MutFormer higher76 ESM-1b higher6
MutFormer higherTieESM-1b higher
Compared
MutFormer, ESM-1b

Not reviewed yet.

MutationTaster and ESM-1b: Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • two-study-conflict
  • unknown

Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods ranks ESM-1b above MutationTaster in 4 of 4 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks MutationTaster above ESM-1b in 5 of 5 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank MutationTaster above ESM-1b in 5 of their 10 comparisons and ESM-1b higher in 4; 1 is a tie. Of those papers, Brandes et al. 2023 ranks ESM-1b higher on its own (4 of 4).

Comparisons in which each paper scores MutationTaster or ESM-1b higher2 other papers: MutationTaster higher in 5, ESM-1b higher in 4, 1 tie.2 other papers5 MutationTaster higher51 tie14 ESM-1b higher4
MutationTaster higherTieESM-1b higher
Compared
MutationTaster, ESM-1b

Not reviewed yet.

MutScore and ESM-1b: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) and An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers disagree

  • Low severity
  • Not yet reviewed
  • two-study-conflict
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks ESM-1b above MutScore in 6 of 7 comparisons; An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers ranks MutScore above ESM-1b in 6 of 6 comparisons. No other study gives a verdict, so neither is the outlier.

2 papers rank MutScore above ESM-1b in 7 of their 13 comparisons and ESM-1b higher in 6. Of those papers, Livesey and Marsh 2025 ranks ESM-1b higher on its own (6 of 7).

Comparisons in which each paper scores MutScore or ESM-1b higher2 other papers: MutScore higher in 7, ESM-1b higher in 6, 0 ties.2 other papers7 MutScore higher76 ESM-1b higher6
MutScore higherTieESM-1b higher
Compared
MutScore, ESM-1b

Not reviewed yet.